



GETINGE

Acquisition of Boston Scientific's
Cardiac and Vascular Surgery
Businesses


Definitive agreement to acquire Boston Scientific's Cardiac and Vascular businesses ("CS/VS") on a debt-free basis for US\$750 million in cash

Implies an EV/EBIT 2006 multiple of 10.4x (excluding synergies)


Including favourable tax benefit of approximately US\$120m, EV/EBIT 2006 multiple of 8.8x (excluding synergies)

To be integrated into Medical Systems business area. Cardiopulmonary division will be renamed Cardiovascular division


Transaction expected to close in December 2007, after clearance from the relevant competition authorities



2006 WW Cardiac Surgery Market - \$2.3 billion



The Cardiac Surgery business participates in US\$0.5 billion of the US\$2.3 billion cardiac surgery market



Overview

Focused on minimally invasive technologies such as endovascular vessel harvesting (“EVH”), surgical ablation, beating heart and anastomosis

Key financials

2006 sales: Total \$189m of which c. 10% was generated outside the US

Employees

450 employees

- 90 sales reps; 90 R&D personnel

Locations

R&D, Commercial & Administration: San Jose, CA

Manufacturing: Dorado, Puerto Rico



About the Cardiac Surgery Division (cont.)

GETINGE


Product	Total US mkt size (\$mm)	Estimated CS mkt share / position	%of CS sales	Competitors
EVH	155	82% / 1	65%	Datascope, Terumo, Teleflex
Beating Heart	130	32% / 2	24%	Medtronic, Teleflex, Estech
Anastomosis	15	75% / 1	7%	Medtronic, Novare
Ablation*	80	15% / 3	4%	Medtronic, AtriCure, ATS, Estech, St. Jude

* Concomitant and standalone

Vascular Surgery* Market Overview

GETINGE

Total WW market US\$300 million
US market US\$170 million




* Synthetic grafts

Overview

Leading supplier of Vascular Surgery products

- #1 in abdominal aortic aneurysm
- #1 in thoracic aortic aneurysm grafts
- Hemashield® Gold—most used vascular graft



Key financials

2006 sales: Total \$84m

Employees


250, all of whom are US based

Locations

Wayne, NJ

Competitors

Terumo, Bard, WL Gore



This acquisition helps Getinge pursue its vision to create a global player in the highly attractive niche cardiac surgery market. Combining CS/VS with its existing Perfusion business will serve as a platform for further organic and acquisition growth

Critical mass

Complementary product portfolios

Complementary geographic coverage

Distribution of the CS/VS products through Medical Systems' global sales and marketing organisation


Distribution of Getinge's perfusion products through CS/VS' US based sales organisation

Complementary product portfolio



Key pro forma financials


US\$m	Year ended 31 December 06
Combined sales	273
EBIT	72
<i>EBIT margin</i>	26.4%
Total assets	140
Total liabilities	17
Goodwill (estimate)	560



We strive to be a global No 1 or No 2 in our core product areas focused. Market leadership will help us attain cost leadership through scale

We strive to combine the strength of our leading product positions and the depth of our know-how to offer innovative solutions that lead to process improvements for our customers

A direct approach to our customers is crucial to our success Getinge will strive to establish own distribution companies whenever justifiable



Q&A